New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
10:43 EDTELX, DRI, LB, ALR, RIO, COO, FOLD, CBSO, SIMO, STAAHigh option volume stocks
High option volume stocks: SIMO CBSO STAA ALR ELX COO LB FOLD RIO DRI
News For SIMO;CBSO;STAA;ALR;ELX;COO;LB;FOLD;RIO;DRI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 18, 2014
16:37 EDTDRIDarden announces restructuring, strategic actions
Darden Restaurants announced several leadership changes and strategic actions in order to increase the focus on restaurant operations and improve the guest experience. These changes will better position Darden to win the battle for market share across all of its concepts. In addition to improving focus and providing better support for the company's restaurants, the announcement will lead to approximately $20M in annualized cost savings through a reduction in General and Administrative expenses. The company expects savings of approximately $10M this fiscal year which will mitigate anticipated near-term cost increases in dairy, beef and other commodities. Darden Interim CEO Gene Lee stated, "Winning market share, improving same-restaurant-sales and achieving best-in-class profitability are our key operational objectives going forward, so we need to fine-tune our approach to the business to make sure we are laser-focused on these initiatives. The actions announced today are critically important steps in becoming more efficient in how we support the restaurants. This includes limiting the number of distractions that divert our attention from what matters most continually working to improve the food and service we offer our guests."
16:35 EDTDRIDarden reports restructuring, closes aviation department, CFO retirement
Subscribe for More Information
13:28 EDTRIOIron ore, steel stocks lower after iron ore prices, China home prices decline
Subscribe for More Information
09:20 EDTFOLDOn The Fly: Pre-market Movers
Subscribe for More Information
November 17, 2014
18:32 EDTFOLDOn The Fly: After Hours Movers
Subscribe for More Information
16:24 EDTFOLDOn The Fly: Closing Wrap
Stocks on Wall Street were quiet and traded in a fairly narrow range for their sixth straight session, despite a "merger Monday" that saw over $100B in deals announced. The Dow and S&P, which began the week near record levels, passed back and forth across the flat line several times during the day, though the Nasdaq weakened early in the session and never really recovered. ECONOMIC EVENTS: In the U.S., industrial production fell 0.1% in October, missing expectations for it to have risen 0.2% from the prior month. October capacity utilization came in at 78.9%, which fell short of the expected 79.3% rate. The Empire State manufacturing index, which reflects manufacturing activity in the New York region, rose 4 points to 10.2 in November, which was generally in-line with the consensus forecast. In Asia, Japan's GDP unexpectedly shrank an annualized 1.6% last quarter, missing projections for a 2.2% gain and sinking its economy into a recession. COMPANY NEWS: Actavis (ACT) gained $4.17, or 1.71%, to $247.94 after confirming that it agreed to acquire Allergan (AGN) for a combination of $129.22 in cash and 0.3683 Actavis shares valued at approximately $66B, or $219 per Allergan share. Valeant Pharmaceuticals (VRX), which had been in a contentious fight to buy Allergan, commented that it "cannot justify to its own shareholders" paying a price of $219 or more per share for the Botox maker, whose stock rose $10.55, or 5.31%, to $209.20... Halliburton (HAL), conversely, fell $5.85, or 10.62%, to $49.23 after it agreed to acquire Baker Hughes (BHI) in a stock and cash transaction valued at $78.62 per Baker Hughes share, representing an enterprise value of $38B. When the deal talks were first reported by The Wall Street Journal last week, antitrust concerns were highlighted by analysts, but Halliburton said it had agreed to divest businesses that generate up to $7.5B in revenues, if required by regulators, and agreed to pay a fee of $3.5B if the transaction terminates due to a failure to obtain required approvals. Baker Hughes rose $5.34, or 8.92%, to $65.23 after the deal was announced. MAJOR MOVERS: Among the notable gainers was Celldex Therapeutics (CLDX), which advanced $4.09, or 28.88%, to $18.25 after the company reported it saw a statistically significant overall survival benefit, along with an increase in clinically meaningful tumor shrinkage, in a sub-group of its study of a drug to treat a specific type of brain tumor. Also higher was Amicus Therapeutics (FOLD), which rose $1.01, or 17.75%, to $6.70 after the company announced additional data on secondary endpoints from its second Phase 3 study of its treatment for Fabry disease. Among the noteworthy losers was William Lyon Homes (WLH), which fell $3.52, or 15.53%, to $19.14 after the company announced that it intends to offer, subject to market and other conditions, 1M tangible equity units, which will consist of a prepaid stock purchase contract and an amortizing note. Also lower were shares of DreamWorks (DWA), which dropped $3.71, or 14.26%, to $22.31 after multiple media outlets reported that talks about a takeover of the company by Hasbro (HAS) had ended. INDEXES: The Dow gained 13.01, or 0.07%, to 17,647.75, the Nasdaq lost 17.54, or 0.37%, to 4,671.00, and the S&P 500 added 1.50, or 0.07%, to 2,041.32.
16:01 EDTFOLDAmicus Therapeutics files to sell $75M in common stock
J.P. Morgan Securities LLC is acting as sole book-running manager for the proposed offering. Cowen and Company, LLC and Leerink Partners are acting as lead managers and Janney Montgomery Scott is acting as co-manager for the offering. The Company expects to use the net proceeds of the offering for investment in the global commercialization infrastructure for migalastat monotherapy for Fabry disease, the continued clinical development of its product candidates and for other general corporate purposes.
09:22 EDTFOLDOn The Fly: Pre-market Movers
Subscribe for More Information
07:47 EDTLBL Brands has strong momentum, says Oppenheimer
Subscribe for More Information
07:20 EDTALRLeerink to hold a tour
Subscribe for More Information
November 16, 2014
14:53 EDTFOLDAmicus announces positive data from Fabry monotherapy study
Amicus Therapeutics announced additional positive data on important secondary endpoints from its second Phase 3 study of the oral small molecule chaperone migalastat HCl for Fabry disease. In a poster1 at the American Society of Nephrology Kidney Week 2014, results were presented from Fabry patients with amenable mutations in Study 012 who switched from standard of care enzyme replacement therapy, ERT, to migalastat as their only therapy for Fabry disease. Data from the Fabry Registry indicate that the leading cause of death in patients is from cardiac complications2. In Study 012, patients who switched from ERT to migalastat showed a statistically significant decrease from baseline to month 18 in left ventricular mass index-LVMi. LVMi is a measure of cardiac hypertrophy, an increase in the size of the heart that has been associated with an increased risk of cardiac events in Fabry patients."Cardiac disease represents a major cause of morbidity and mortality in Fabry patients that is not adequately addressed with currently available treatment," said Professor Ales Linhart, MD, PhD, a leading expert in the cardiac manifestations of Fabry disease from Charles University of Prague. "The data showing further regression of left ventricular mass in patients switched from ERT to migalastat in this study are very promising since in other cardiac conditions a reduction of cardiac mass typically translates to significant improvements in long term outcomes."
November 13, 2014
08:35 EDTDRIDarden announces corporate governance reforms
Darden Restaurants is implementing a number of reforms and the board has also recommended changes that would require shareholder approval at the company's 2015 Annual Meeting of Shareholders. The changes include, but are not limited to: termination of the company's Shareholder Rights Plan the company has eliminated the Poison Pill by amending the Rights Agreement to expire on November 28, 2014 rather than May 25, 2015; the company has adopted a majority voting standard in uncontested elections; the company has amended its political engagement and disclosure policy to provide additional disclosure of its political contributions and lobbying efforts; the board has resolved to recommend for shareholder approval, at the company's next annual meeting, an amendment to the Charter to provide a 10% voting threshold to call a special meeting; the board has recommended for shareholder approval an amendment to the relevant provisions of the Charter to eliminate the supermajority requirement. The board also adopted a revised peer group for compensation benchmarking, which better matches the company's size and profile. This new peer group will assist the board in further aligning compensation practices with shareholder interests.
November 12, 2014
08:12 EDTFOLDSeeThruEquity to hold a conference
Subscribe for More Information
November 11, 2014
10:00 EDTDRIOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alcentra Capital (ABDC) upgraded to Outperform from Market Perform at Keefe Bruyette... Ambac Financial (AMBC) upgraded to Neutral from Sell at MKM Partners... Banco Bilbao (BBVA) upgraded to Buy from Reduce at Nomura... Darden (DRI) upgraded at KeyBanc... ICU Medical (ICUI) upgraded to Overweight from Neutral at Piper Jaffray... IMAX (IMAX) upgraded to Buy from Neutral at Goldman... Juniper (JNPR) upgraded to Buy from Neutral at Nomura... Michaels (MIK) upgraded to Overweight from Equal Weight at Morgan Stanley... Midcoast Energy (MEP) upgraded to Outperform from Neutral at Credit Suisse... Midstates Petroleum (MPO) upgraded to Outperform from Market Perform at Northland... Monroe Capital (MRCC) upgraded to Outperform from Neutral at RW Baird... NuVasive (NUVA) upgraded to Outperform from Market Perform at Cowen... ONEOK Partners (OKS) upgraded to Outperform from Neutral at Credit Suisse... ORBCOMM (ORBC) upgraded to Overweight from Equal Weight at First Analysis... Pattern Energy (PEGI) upgraded to Outperform from Neutral at Macquarie... Targa Resources Partners (NGLS) upgraded to Outperform from Neutral at Credit Suisse... Time Warner (TWX) upgraded to Conviction Buy from Neutral at Goldman... Tremor Video (TRMR) upgraded to Buy from Hold at Jefferies... Western Gas Partners (WES) upgraded to Outperform from Neutral at Credit Suisse... Yamana Gold (AUY) upgraded to Overweight from Neutral at HSBC... Zynga (ZNGA) upgraded to Buy from Hold at Jefferies.
08:55 EDTDRIDarden upgraded at KeyBanc
Subscribe for More Information
06:43 EDTDRIDarden upgraded to Buy from Hold at KeyBanc
November 10, 2014
15:54 EDTFOLDAmerican Society of Nephrology to hold a conference
Subscribe for More Information
07:22 EDTLBU.S. Retail Softlines sector downgraded to Negative at Barclays
Subscribe for More Information
05:48 EDTLBU.S. Retail Softlines industry cut to Negative at Barclays
Subscribe for More Information
November 9, 2014
13:10 EDTRIORio Tinto CEO defends iron-ore expansion moves, WSJ says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use